Hamilton Thorne (CVE:HTL) last released its earnings results on Thursday, May 24th. The company reported C$0.01 EPS for the quarter. Hamilton Thorne had a net margin of 10.14% and a return on equity of 16.18%. The firm had revenue of C$8.85 million for the quarter.
HTL stock opened at C$1.11 on Tuesday. Hamilton Thorne has a one year low of C$0.67 and a one year high of C$1.19.
In other news, insider Keith Edwards sold 30,250 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of C$0.90, for a total value of C$27,225.00. Insiders sold 48,750 shares of company stock worth $45,080 in the last three months.
About Hamilton Thorne
Hamilton Thorne Ltd., together with its subsidiary, Hamilton Thorne, Inc, develops, manufactures, and sells precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell, and developmental biology research markets. The company offers clinical lasers, such as LYKOS and ZILOS-tk lasers, as well as clinical laser software and hardware for clinical assisted reproduction; and research lasers, including XYRCOS and XYClone lasers for stem cell research, gene targeting, knock out mouse production, SCNT, ICSI, IVF, and assisted hatching applications, as well as Stiletto lasers for isolation of cells of interest, ablation of unwanted cells, and precision scoring of cell colonies.
Read More: Should you buy a closed-end mutual fund?
Receive News & Ratings for Hamilton Thorne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hamilton Thorne and related companies with MarketBeat.com's FREE daily email newsletter.